Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
Calls to poison centers about high-powered magnets increased by 444% after ban lifted
15 March 202113 things primary care clinics can check to help preserve brain health
15 March 2021Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a new study led by researchers from The University of Texas MD Anderson Cancer Center.
